EP1638566A4 - Imidazo-quinolines a substitution sulfonamide - Google Patents

Imidazo-quinolines a substitution sulfonamide

Info

Publication number
EP1638566A4
EP1638566A4 EP04756208A EP04756208A EP1638566A4 EP 1638566 A4 EP1638566 A4 EP 1638566A4 EP 04756208 A EP04756208 A EP 04756208A EP 04756208 A EP04756208 A EP 04756208A EP 1638566 A4 EP1638566 A4 EP 1638566A4
Authority
EP
European Patent Office
Prior art keywords
sulfonamide substituted
substituted imidazoquinolines
imidazoquinolines
sulfonamide
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04756208A
Other languages
German (de)
English (en)
Other versions
EP1638566A2 (fr
Inventor
George W Griesgraber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coley Pharmaceutical Group Inc
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Publication of EP1638566A2 publication Critical patent/EP1638566A2/fr
Publication of EP1638566A4 publication Critical patent/EP1638566A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP04756208A 2003-06-27 2004-06-25 Imidazo-quinolines a substitution sulfonamide Withdrawn EP1638566A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48320003P 2003-06-27 2003-06-27
PCT/US2004/020607 WO2005003065A2 (fr) 2003-06-27 2004-06-25 Imidazo-quinolines a substitution sulfonamide

Publications (2)

Publication Number Publication Date
EP1638566A2 EP1638566A2 (fr) 2006-03-29
EP1638566A4 true EP1638566A4 (fr) 2009-03-25

Family

ID=33563911

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04756208A Withdrawn EP1638566A4 (fr) 2003-06-27 2004-06-25 Imidazo-quinolines a substitution sulfonamide

Country Status (16)

Country Link
EP (1) EP1638566A4 (fr)
JP (1) JP2007521280A (fr)
KR (1) KR20060035637A (fr)
CN (1) CN1812789B (fr)
AR (2) AR044922A1 (fr)
AU (1) AU2004253929A1 (fr)
BR (1) BRPI0411916A (fr)
CA (1) CA2529322A1 (fr)
IL (1) IL172427A0 (fr)
MX (1) MXPA06000144A (fr)
MY (1) MY157827A (fr)
NZ (1) NZ544330A (fr)
RU (1) RU2374246C2 (fr)
TW (2) TW200511992A (fr)
WO (2) WO2005003065A2 (fr)
ZA (1) ZA200600769B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
BRPI0412902A (pt) 2003-08-12 2006-09-26 3M Innovative Properties Co compostos contendo imidazo substituìdo por oxima
WO2005020999A1 (fr) 2003-08-27 2005-03-10 3M Innovative Properties Company Imidazoquinolines substituees par aryloxy et arylalkyleneoxy
US20050054665A1 (en) 2003-09-05 2005-03-10 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
ES2544477T3 (es) 2003-10-03 2015-08-31 3M Innovative Properties Company Imidazoquinolinas sustituidas con alcoxi
ES2584863T3 (es) 2003-10-03 2016-09-29 3M Innovative Properties Company Pirazolopiridinas y análogos de las mismas
CA2545825A1 (fr) 2003-11-14 2005-06-02 3M Innovative Properties Company Composes d'un anneau d'imidazo substitue par hydroxylamine
CN1906193A (zh) 2003-11-14 2007-01-31 3M创新有限公司 肟取代的咪唑环化合物
NZ547467A (en) 2003-11-25 2010-06-25 3M Innovative Properties Co Substituted imidazo ring system and methods
JP2007513165A (ja) * 2003-12-02 2007-05-24 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物を含む併用薬および治療方法
WO2005066170A1 (fr) 2003-12-29 2005-07-21 3M Innovative Properties Company Imidazoquinolines a substitution arylalcenyle et arylalkynyle
JP2007517044A (ja) 2003-12-30 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー イミダゾキノリニル、イミダゾピリジニル、およびイミダゾナフチリジニルスルホンアミド
AU2005228150A1 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (fr) 2004-06-15 2005-12-29 3M Innovative Properties Company Imidazoquinolines et imidazonaphthyridines substituees par un heterocyclyle contenant un azote
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006009826A1 (fr) 2004-06-18 2006-01-26 3M Innovative Properties Company Thiazoloquinolines et thiazolonaphtyridines substitues par aryloxy et arylalkyleneoxy
WO2006065280A2 (fr) 2004-06-18 2006-06-22 3M Innovative Properties Company Composes a noyau imidazo a substitutif d'isoxazole, de dihydroisoxazole et d'oxadiazole
US7943609B2 (en) 2004-12-30 2011-05-17 3M Innovative Proprerties Company Chiral fused [1,2]imidazo[4,5-C] ring compounds
JP2008526752A (ja) * 2004-12-30 2008-07-24 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤化合物の多経路投与
WO2006083440A2 (fr) 2004-12-30 2006-08-10 3M Innovative Properties Company Composes chiraux [1,2]imidazo[4,5-c] substitues a noyau fusionne
JP2008530022A (ja) 2005-02-04 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫反応調節物質を含む水性ゲル処方物
US20080318998A1 (en) 2005-02-09 2008-12-25 Coley Pharmaceutical Group, Inc. Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines
AU2006213746A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
CA2602590A1 (fr) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Composes cycliques 1-pyrazolo[3,4-c] substitues comme modulateurs de la biosynthese de cytokine destines au traitement d'infections virales et de maladies neoplastiques
ZA200803029B (en) * 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
JP2009507856A (ja) * 2005-09-09 2009-02-26 コーリー ファーマシューティカル グループ，インコーポレイテッド Ｎ−｛２−［４−アミノ−２−（エトキシメチル）−１Ｈ−イミダゾ［４，５−ｃ］キノリン−１−イル］−１，１−ジメチルエチル｝メタンスルホンアミドのアミドおよびカルバマート誘導体ならびに方法
KR20080048551A (ko) * 2005-09-23 2008-06-02 콜레이 파마시티컬 그룹, 인코포레이티드 1Ｈ-이미다조[4,5-ｃ]피리딘 및 그의 유사체의 제조법
US8951528B2 (en) 2006-02-22 2015-02-10 3M Innovative Properties Company Immune response modifier conjugates
WO2008008432A2 (fr) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Composés à cycle [1,2] imidazo [4,5-c] fusionné chiral substitué et procédés correspondants
CA2719544C (fr) * 2008-03-24 2018-01-09 4Sc Ag Imidazoquinolines substituees
ES2617451T3 (es) 2010-08-17 2017-06-19 3M Innovative Properties Company Composiciones lipidadas de compuestos modificadores de la respuesta inmunitaria, formulaciones, y métodos
JP6460789B2 (ja) 2011-06-03 2019-01-30 スリーエム イノベイティブ プロパティズ カンパニー ポリエチレングリコールセグメントを有するヘテロ２官能性リンカー及び該リンカーから調製された免疫反応調節複合体
US9107958B2 (en) 2011-06-03 2015-08-18 3M Innovative Properties Company Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
EP3350178B1 (fr) * 2015-09-14 2021-10-20 Pfizer Inc. Nouveaux dérivés imidazo [4,5-c]quinoline et imidazo [4,5-c][1,5]naphthyridine utilisés comme inhibiteurs de lrrk2
KR20230149857A (ko) 2016-07-07 2023-10-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
KR102582626B1 (ko) 2017-03-10 2023-09-22 화이자 인코포레이티드 Lrrk2 억제제로서의 신규 이미다조[4,5-c]퀴놀린 유도체
HUE058995T2 (hu) 2017-09-06 2022-10-28 BioNTech SE Szubsztituált imidazokinolinok mint a TLR7 agonistái
CA3086439A1 (fr) 2017-12-20 2019-06-27 3M Innovative Properties Company Composes imidazo [4,5-c]quinoleine a substitution amide ayant un groupe de liaison a chaine ramifiee destines a etre utilises en tant que modificateur de la reponse immunitaire
WO2020190725A1 (fr) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugués ciblant le her2
AU2020407871A1 (en) * 2019-12-20 2022-06-30 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076519A1 (fr) * 1999-06-10 2000-12-21 3M Innovative Properties Company Imidazoquinolines substituees sulfonamide et sulfamide
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005513021A (ja) * 2001-11-16 2005-05-12 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物およびトール様受容体経路に関する方法および組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076519A1 (fr) * 1999-06-10 2000-12-21 3M Innovative Properties Company Imidazoquinolines substituees sulfonamide et sulfamide
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines

Also Published As

Publication number Publication date
CN1812789A (zh) 2006-08-02
JP2007521280A (ja) 2007-08-02
CN1812789B (zh) 2010-07-14
WO2005003064A2 (fr) 2005-01-13
MXPA06000144A (es) 2006-04-07
WO2005003065A3 (fr) 2005-03-10
WO2005003064A3 (fr) 2005-03-31
BRPI0411916A (pt) 2006-08-15
MY157827A (en) 2016-07-29
RU2005138915A (ru) 2006-06-27
CA2529322A1 (fr) 2005-01-13
AR044923A1 (es) 2005-10-12
WO2005003065A2 (fr) 2005-01-13
NZ544330A (en) 2009-06-26
ZA200600769B (en) 2007-05-30
AU2004253929A1 (en) 2005-01-13
EP1638566A2 (fr) 2006-03-29
IL172427A0 (en) 2006-04-10
KR20060035637A (ko) 2006-04-26
TW200514784A (en) 2005-05-01
RU2374246C2 (ru) 2009-11-27
AR044922A1 (es) 2005-10-12
TW200511992A (en) 2005-04-01

Similar Documents

Publication Publication Date Title
IL172427A0 (en) Sulfonamide substituted imidazoquinolines
ZA200603879B (en) Substituted indazole-O-glucosides
IL175490A0 (en) Substituted indazole-o-glucosides
EP1663113A4 (fr) Sulfonamides substitues
ZA200603880B (en) Substituted indole-O-glucosides
EP1680131A4 (fr) Indole- o -glucosides substitues
HK1088602A1 (en) 2-pyridinecarboxamide derivatives
HK1088326A1 (en) Piperidine-benzenesulfonamide derivatives
HK1089443A1 (en) Imidazol-4-yl-ethynyl-pyridine derivatives
GB0317665D0 (en) Qinazoline derivatives
PT1682493E (pt) Derivados de aminoacetonitrilo
IL175189A0 (en) N-thiazol-2-yl-benzamide derivatives
TWI368482B (en) New 2-pyridinylethylbenzamide derivatives
GB0329314D0 (en) Substituted arylpyrazoles
ZA200600430B (en) Substituted spirobenzazepines
SI1706373T1 (sl) Amidoacetonitrilni derivati
GB0316128D0 (en) Novel sulfonamide compounds
GB0319793D0 (en) Pyridinylmorpholine derivatives
TW573910U (en) Pivot
AU2003263871A8 (en) Abiogenic transition unit
TWI341309B (en) Heteroarylcarbamoylbenzene derivatives
SI1654253T1 (sl) Substituirani 3-pirolidin-indolni derivati
AU2834P (en) Baltinblus Gaura lindheimeri
AU2833P (en) Baltinrose Gaura lindheimeri
GB0307514D0 (en) Double articulated rule

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060110

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20090223

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: COLEY PHARMACEUTICAL GROUP, INC.

17Q First examination report despatched

Effective date: 20090903

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: COLEY PHARMACEUTICAL GROUP, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100515